Prevention of anticipatory nausea and vomiting secondary to chemotherapy: assessing the efficacy of alprozolam versus placebo.
Doganavsargil, O. (2006) Prevention of anticipatory nausea and vomiting secondary to chemotherapy: assessing the efficacy of alprozolam versus placebo. Psychiatry in Turkiye, 8 (1). pp. 22-26.
Full text available as:
Objective: Some authors suggest that benzodiazepines should be routinely used in chemotherapy. Double-blind, crossover and placebo controlled study was aimed to compare efficacy of alprozolam and cisplatin combination or cisplatin and placebo combination to reduce anticiparotory nausea and vomiting. Method: 14 patients with gynecological cancer were recruited. All patient received cisplatin chemotherapy. We established two groups of patient randomly. Patients in group P received 5-HT3 8 mg/day in combination with placebo and patients in group A received 5-HT3 in combination with alprozolam. All patients were given 5-HT3 8 mg daily in all cures. n first cure; Alprozolam 0,25 mg tablets or placebo was given a three times a day for three days. First dose was given before chemotherapy infusion. In second cure, they received placebo instead of alprozolam or alprozolam instead of placebo for crossover. Patients filled Scale of State Anxiety Inventory (STAI) and scale for duration of nausea and vomiting episodes for the first three days of chemotherapy. In the next cure, new scales were filled. Result and conclusion: Two groups were compared for number of vomiting episodes, duration of nausea, trait anxiety scores for three days. There were no significant differences between groups (p>0.05). There were no correlation between groups for anxiety scores, duration of nausea, number of the vomiting and age, stage, number of chemotherapy, duration since diagnose (p>0.01). Routine administration of benzodiazepines should be interrogated for each patient who received chemotherapy.
Archive Staff Only: edit this record